In a subsequent phase I trial, ten patients with NRAS-mutant melanoma, one patient with wild type NRAS melanoma, and eight melanoma patients of unknown NRAS status received both tivantinib and sorafenib. The gene discussed is NRAS; the disease is melanoma.